rAAV Production With HDAC Inhibitors for Scalable GMP Yield
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for large-scale, GMP-compliant production of recombinant Adeno-Associated Virus (rAAV) particles are costly and inefficient, hindering widespread adoption of rAAV-based gene therapies.
Innovation Solution
Culturing cells capable of producing rAAV particles in the presence of histone deacetylase (HDAC) inhibitors, such as sodium valproate or sodium propionate, at specific concentrations, followed by a series of purification steps including depth filtration, tangential flow filtration, and chromatography to enhance rAAV yield.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods are used for large-scale production of rAAV particles, then production can be maintained at existing levels, but production cost remains high and scalability is limited
Solution Approach 1:
The patent applies parameter changes by modifying culture conditions through the addition of HDAC inhibitors (such as sodium butyrate or sodium propionate) at specific concentrations (e.g., 5-20 mM) and maintaining them for defined periods (e.g., 24-72 hours). These parameter changes in chemical environment trigger enhanced gene expression and protein production, resulting in 2-fold or greater increases in rAAV particle yield without requiring changes to the fundamental production process or infrastructure.
2Productivity
If production scale is increased to meet clinical demand, then more rAAV particles can be produced, but manufacturing complexity and cost increase
Solution Approach 1:
The patent employs a disposable approach by using simple, inexpensive chemical additives (HDAC inhibitors like sodium butyrate or propionate) that can be easily added to and removed from culture media. These small-molecule inhibitors are cost-effective, readily available, and do not require complex delivery systems or specialized equipment, thereby enabling scale-up without proportionally increasing manufacturing complexity.
3Productivity
If HDAC inhibitors are added to enhance rAAV production, then particle yield increases two-fold or more, but additional process steps are required
Solution Approach 1:
The patent merges the HDAC inhibitor addition step with existing culture maintenance operations. The inhibitors are added directly to the culture media at routine time points (e.g., during mid-log phase or at specific hours post-transfection), combining the enhancement function with standard culture procedures. This integration minimizes additional operational steps while achieving the productivity boost.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in a two-fold or higher increase in rAAV yield, significantly reducing production costs and enabling scalable, cost-effective manufacturing processes compliant with Good Manufacturing Practice (GMP) regulations.
Implementation Method 1
culturing cells capable of producing rAAV particles in the presence of an effective amount of a histone deacetylase (HDAC) inhibitor under conditions that allow the production of the rAAV particles
Data Source
AI summary
Provided herein are improved methods for producing recombinant Adeno-Associated Virus (rAAV) particles. In some embodiments, a method for producing recombinant AAV (rAAV) particles provided herein comprises culturing cells capable of producing rAAV particles in the presence of a histone deacetylase (HDAC) inhibitor. In some embodiments, a method for producing recombinant AAV (rAAV) particles provided herein comprises culturing cells capable of producing rAAV particles in the presence of a histone deacetylase (HDAC) inhibitor and increased amount of a sodium salt.